LETERMOVIR ELIMINATES SURVIVAL DIFFERENCES ACROSS RECIPIENT/DONOR CMV SEROLOGY COMBINATIONS IN MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION (EBMT 2026) - Feb 7, 2026 - Abstract #OS10-06; Pres time: Mar 24, 2026; 11:45 AM - 11:54 AM; Location: N101-102; "Letermovir prophylaxis was associated with elimination of the historically observed survival differences across all recipient/donor CMV serostatus combinations in MUD allo-SCT. These findings suggest a profound reduction in CMV-related risk heterogeneity and support routine letermovir use in CMV-seropositive recipients, with implications for donor selection and post-transplant risk stratification."
Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Transplantation
|
|
Radwan Massoud1; Lara Demann1; Claudia Langebrake1; Dietlinde Janson1; Mirjam Reichard1; Rusudan Sabauri1; Maroly Bohorquez Manjarres1; Benno Lickefett1; Jette Luedersen1; Max Wichmann1; Sophia Oechsler1; Rolf Krause1; Gaby Zeck1; Silke Heidenreich1; Christian Niederwieser1; Mathias Schäfersküpper1; Franziska E. Marquard1; Maraike Harfmann1; Gunnar Weise1; Kristin Rathje1; Jochim Reinert1; Nico Gagelmann1; Ina Rudolph1; Catherina Lueck1; Evgeny Klyuchnikov1; Christine Wolschke1; Nicolaus Kröger1; Francis Ayuk1
|